Continuous glucose monitors, or CGMs, are designed for people with type 1 diabetes who need to know their levels to adjust their insulin therapy. They are also used by people with type 2 diabetes, but have also begun to be sold to people without diabetes, sometimes marketed as a way to optimise health.
But a review conducted by researchers at the University of Gothenburg, among others, shows that there is a lack of scientific support for the claim that CGMs lead to better health or prevent disease in people without diabetes.
The researchers warn instead that normal variations in blood sugar risk being overinterpreted and causing concern.
